Resources
64 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 10/7/2019 (updated 3/25/2024)
Mapping Your Way from Vision to Impact: Strategic Planning Tools and Tips (Panel Discussion) Presentation and Resources.
Posted 10/7/2019 (updated 3/25/2024)
The Adopting a Shared Framework for Community Collaboration webinar addresses new questions and comments about the development of a shared public health framework, strategic planning, consortium partners, and opioid use disorder treatment.
Posted 10/7/2019 (updated 3/25/2024)
Mapping Your Way from Vision to Impact: Strategic Planning Tools and Tips Webinar Presentation and Materials
Posted 10/7/2019 (updated 3/25/2024)
An Introduction to Harm Reduction Webinar Presentation and Materials
Posted 10/7/2019 (updated 3/25/2024)
Adopting a Shared Framework for Community Collaboration Webinar and Resources
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 4/12/2022 (updated 3/27/2024)
OMNI Institute, in partnership with the JBS RCORP-TA team, had five sessions of the Data Learning Collaborative (LC).
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.
Posted 4/4/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration (FDA) announced that the makers of Narcan, an opioid overdose treatment, have the agency’s approval to make the drug widely available over the counter (OTC). Narcan is the brand name of the drug naloxone, a fast-acting overdose reversal. Until now, availability varied by state – typically restricted to licensed health care providers, approved opioid overdose programs, and first responders. This is an important consideration for rural counties given that research shows that these areas are nearly three times more likely than metropolitan counties to be a low-dispensing county for naloxone.
Posted 10/24/2022 (updated 3/27/2024)
In this session, we will give an overview of the program, discuss expectations, grant deliverables, and highlight trends in psychostimulant use. We will also discuss the role of the HRSA Project Officer, Grants Management Specialist, Technical Expert Leads, and Evaluation Team.